187 related articles for article (PubMed ID: 19366807)
1. AZD1152 rapidly and negatively affects the growth and survival of human acute myeloid leukemia cells in vitro and in vivo.
Oke A; Pearce D; Wilkinson RW; Crafter C; Odedra R; Cavenagh J; Fitzgibbon J; Lister AT; Joel S; Bonnet D
Cancer Res; 2009 May; 69(10):4150-8. PubMed ID: 19366807
[TBL] [Abstract][Full Text] [Related]
2. Aurora kinase inhibitor AZD1152 negatively affects the growth and survival of HTLV-1-infected T lymphocytes in vitro.
Tomita M; Tanaka Y; Mori N
Int J Cancer; 2010 Oct; 127(7):1584-94. PubMed ID: 20091867
[TBL] [Abstract][Full Text] [Related]
3. Effects of the aurora kinase inhibitors AZD1152-HQPA and ZM447439 on growth arrest and polyploidy in acute myeloid leukemia cell lines and primary blasts.
Walsby E; Walsh V; Pepper C; Burnett A; Mills K
Haematologica; 2008 May; 93(5):662-9. PubMed ID: 18367484
[TBL] [Abstract][Full Text] [Related]
4. AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo.
Yang J; Ikezoe T; Nishioka C; Tasaka T; Taniguchi A; Kuwayama Y; Komatsu N; Bandobashi K; Togitani K; Koeffler HP; Taguchi H; Yokoyama A
Blood; 2007 Sep; 110(6):2034-40. PubMed ID: 17495131
[TBL] [Abstract][Full Text] [Related]
5. The FLT3 internal tandem duplication mutation is a secondary target of the aurora B kinase inhibitor AZD1152-HQPA in acute myelogenous leukemia cells.
Grundy M; Seedhouse C; Shang S; Richardson J; Russell N; Pallis M
Mol Cancer Ther; 2010 Mar; 9(3):661-72. PubMed ID: 20159992
[TBL] [Abstract][Full Text] [Related]
6. The topoisomerase I poison CPT-11 enhances the effect of the aurora B kinase inhibitor AZD1152 both in vitro and in vivo.
Nair JS; de Stanchina E; Schwartz GK
Clin Cancer Res; 2009 Mar; 15(6):2022-30. PubMed ID: 19276280
[TBL] [Abstract][Full Text] [Related]
7. Antineoplastic effects of an Aurora B kinase inhibitor in breast cancer.
Gully CP; Zhang F; Chen J; Yeung JA; Velazquez-Torres G; Wang E; Yeung SC; Lee MH
Mol Cancer; 2010 Feb; 9():42. PubMed ID: 20175926
[TBL] [Abstract][Full Text] [Related]
8. p53 is critical for the Aurora B kinase inhibitor-mediated apoptosis in acute myelogenous leukemia cells.
Ikezoe T; Yang J; Nishioka C; Yokoyama A
Int J Hematol; 2010 Jan; 91(1):69-77. PubMed ID: 20013323
[TBL] [Abstract][Full Text] [Related]
9. Dual Targeting of Aurora Kinases with AMG 900 Exhibits Potent Preclinical Activity Against Acute Myeloid Leukemia with Distinct Post-Mitotic Outcomes.
Payton M; Cheung HK; Ninniri MSS; Marinaccio C; Wayne WC; Hanestad K; Crispino JD; Juan G; Coxon A
Mol Cancer Ther; 2018 Dec; 17(12):2575-2585. PubMed ID: 30266802
[TBL] [Abstract][Full Text] [Related]
10. P-glycoprotein and breast cancer resistance protein in acute myeloid leukaemia cells treated with the aurora-B kinase inhibitor barasertib-hQPA.
Grundy M; Seedhouse C; Russell NH; Pallis M
BMC Cancer; 2011 Jun; 11():254. PubMed ID: 21679421
[TBL] [Abstract][Full Text] [Related]
11. Identification of genes that confer tumor cell resistance to the aurora B kinase inhibitor, AZD1152.
Guo J; Anderson MG; Tapang P; Palma JP; Rodriguez LE; Niquette A; Li J; Bouska JJ; Wang G; Semizarov D; Albert DH; Donawho CK; Glaser KB; Shah OJ
Pharmacogenomics J; 2009 Apr; 9(2):90-102. PubMed ID: 19188929
[TBL] [Abstract][Full Text] [Related]
12. Optimizing Therapeutic Effect of Aurora B Inhibition in Acute Myeloid Leukemia with AZD2811 Nanoparticles.
Floc'h N; Ashton S; Taylor P; Trueman D; Harris E; Odedra R; Maratea K; Derbyshire N; Caddy J; Jacobs VN; Hattersley M; Wen S; Curtis NJ; Pilling JE; Pease EJ; Barry ST
Mol Cancer Ther; 2017 Jun; 16(6):1031-1040. PubMed ID: 28292940
[TBL] [Abstract][Full Text] [Related]
13. Inhibitor of Aurora Kinase B Induces Differentially Cell Death and Polyploidy via DNA Damage Response Pathways in Neurological Malignancy: Shedding New Light on the Challenge of Resistance to AZD1152-HQPA.
Zekri A; Ghaffari SH; Yaghmaie M; Estiar MA; Alimoghaddam K; Modarressi MH; Ghavamzadeh A
Mol Neurobiol; 2016 Apr; 53(3):1808-1823. PubMed ID: 25752998
[TBL] [Abstract][Full Text] [Related]
14. The aurora B kinase inhibitor AZD1152 sensitizes cancer cells to fractionated irradiation and induces mitotic catastrophe.
Tao Y; Leteur C; Calderaro J; Girdler F; Zhang P; Frascogna V; Varna M; Opolon P; Castedo M; Bourhis J; Kroemer G; Deutsch E
Cell Cycle; 2009 Oct; 8(19):3172-81. PubMed ID: 19755861
[TBL] [Abstract][Full Text] [Related]
15. Enhancement of radiation response in p53-deficient cancer cells by the Aurora-B kinase inhibitor AZD1152.
Tao Y; Zhang P; Girdler F; Frascogna V; Castedo M; Bourhis J; Kroemer G; Deutsch E
Oncogene; 2008 May; 27(23):3244-55. PubMed ID: 18084327
[TBL] [Abstract][Full Text] [Related]
16. Inhibiting the aurora B kinase potently suppresses repopulation during fractionated irradiation of human lung cancer cell lines.
Sak A; Stuschke M; Groneberg M; Kübler D; Pöttgen C; Eberhardt WE
Int J Radiat Oncol Biol Phys; 2012 Oct; 84(2):492-9. PubMed ID: 22381900
[TBL] [Abstract][Full Text] [Related]
17. Effects of selective inhibitors of Aurora kinases on anaplastic thyroid carcinoma cell lines.
Baldini E; Tuccilli C; Prinzi N; Sorrenti S; Antonelli A; Gnessi L; Morrone S; Moretti C; Bononi M; Arlot-Bonnemains Y; D'Armiento M; Ulisse S
Endocr Relat Cancer; 2014 Oct; 21(5):797-811. PubMed ID: 25074669
[TBL] [Abstract][Full Text] [Related]
18. Significance of AZD1152 as a potential treatment against Aurora B overexpression in acute promyelocytic leukemia.
Ghanizadeh-Vesali S; Zekri A; Zaker F; Zaghal A; Yousefi M; Alimoghaddam K; Ghavamzadeh A; Ghaffari SH
Ann Hematol; 2016 Jun; 95(7):1031-42. PubMed ID: 27091351
[TBL] [Abstract][Full Text] [Related]
19. Aurora kinases in childhood acute leukemia: the promise of aurora B as therapeutic target.
Hartsink-Segers SA; Zwaan CM; Exalto C; Luijendijk MW; Calvert VS; Petricoin EF; Evans WE; Reinhardt D; de Haas V; Hedtjärn M; Hansen BR; Koch T; Caron HN; Pieters R; Den Boer ML
Leukemia; 2013 Mar; 27(3):560-8. PubMed ID: 22940834
[TBL] [Abstract][Full Text] [Related]
20. A novel treatment strategy targeting Aurora kinases in acute myelogenous leukemia.
Ikezoe T; Yang J; Nishioka C; Tasaka T; Taniguchi A; Kuwayama Y; Komatsu N; Bandobashi K; Togitani K; Koeffler HP; Taguchi H
Mol Cancer Ther; 2007 Jun; 6(6):1851-7. PubMed ID: 17541033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]